title: [Pharmaceutical product quality control and good manufacturing practices].
abstract: This report describes the roles of Good Manufacturing Practices (GMP) in pharmaceutical product quality control. There are three keys to pharmaceutical product quality control. They are specifications, thorough product characterization during development, and adherence to GMP as the ICH Q6A guideline on specifications provides the most important principles in its background section. Impacts of the revised Pharmaceutical Affairs Law (rPAL) which became effective in 2005 on product quality control are discussed. Progress of ICH discussion for Pharmaceutical Development (Q8), Quality Risk Management (Q9) and Pharmaceutical Quality System (Q10) are reviewed. In order to reconstruct GMP guidelines and GMP inspection system in the regulatory agencies under the new paradigm by rPAL and the ICH, a series of Health Science studies were conducted. For GMP guidelines, product GMP guideline, technology transfer guideline, laboratory control guideline and change control system guideline were written. For the GMP inspection system, inspection check list, inspection memo and inspection scenario were proposed also by the Health Science study groups. Because pharmaceutical products and their raw materials are manufactured and distributed internationally, collaborations with other national authorities are highly desired. In order to enhance the international collaborations, consistent establishment of GMP inspection quality system throughout Japan will be essential.
authors.affiliation: hiyama@nihs.go.jp
authors.forename: Yukio
authors.initials: Y
authors.lastname: Hiyama
mesh_terms: D004345:Drug Industry / Q000331:legislation & jurisprudence* / Q000592:standards*; D017408:Guidelines as Topic; D007564:Japan; D007880:Legislation, Drug; D004364:Pharmaceutical Preparations / Q000592:standards*; D011786:Quality Control; D012308:Risk Management
chemical_list: D004364:Pharmaceutical Preparations